Leukemia / Lymphoma Protocols / Clinical Studies

For information on these and other studies, referring physicians may e-mail protocolinfo@stjude.org or call toll free physician referral line, 1-888-226-4343. If you are not a physician, please e-mail info@stjude.org for information on St. Jude studies.


A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

For: Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma


A Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and of Natural Killer Cell Transplantation Versus Conventional Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

For: acute myeloid leukemia (AML)


A Phase I Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+Positively-Selected Autologous Hematopoietic Stem Cells In Children With High-Risk Solid Tumors or Lymphomas

For: high-risk solid tumors and lymphomas


Adcetris® (Brentuximab Vedotin) Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL) Diseases: High risk Hodgkin Lymphoma

For: High risk Hodgkin lymphoma


Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

For: Hodgkin lymphoma


First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin's Lymphoma in Children and Adolescents

For: Lymphocyte predominant Hodgkin lymphoma


HLA - Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less than 2 Years of Age with Hematologic Malignancies

For: Leukemias (high risk hematologic malignancies)


Study for Newly Diagnosed patients with Acute Lymphoblastic Lymphoma

For: Acute lymphoblastic leukemia


A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors or Lymphomas

For: Relapsed or refractory solid tumors or lymphomas


A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies

For: Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia


A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory Leukemia or Myelodysplastic Syndrome

For: Relapsed or refractory leukemia or hematologic malignancies


Mature B-Cell Lymphoma and Leukemia Study III

For: Leukemia and lymphoma


Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia

For: Acute Lymphoblastic Leukemia


Non St. Jude Protocols


A Phase I Study of Crizotinib (IND#105573) In Combination with Conventional Chemotherapy For Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

For: Relapsed or refractory solid tumors or anaplastic large cell lymphoma


A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-Met, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma

For: Relapses/refractory solid tumors and anaplastic large cell lymphoma


A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia

For: Relapsed or refractory B-precursor acute lymphoblastic leukemia


A phase II a, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the humanized anti-CD19 antibody MOR00208 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

For: Relapsed or refractory B-cell acute lymphoblastic leukemia


Killer Immunoglobulin-Like Receptor (KIR) Incompatible Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children’s Oncology Group (COG) Study (AAML05P1)

For: Refractory and relapsed acute myelogenous leukemia (AML)


A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL (TACL protocol T2009-003)

For: Relapsed ALL


A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma (AHOD1221)

For: Relapsed or Refractory Hodgkin Lymphoma


Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

For: For survivors of Hodgkin lymphoma


A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

For: Leukemia and other blood diseases


A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide) in T-ALL Relapse: A Joint Study of TACL and POETIC

For: Leukemia


A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies

For: Relapsed acute lymphoblastic leukemia [ALL], acute myelogenous leukemia [AML], Hodgkin disease [HD] and non-Hodgkin’s lymphomas [NHL]